open-angle glaucoma

Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
How oral and dental hygiene plays a role in glaucomaIn the past couple of years, there has been discussion regarding dental and oral health—specifically the oral biomicrome—as possibly having a relationship to glaucoma.
Multiple next-generation stents lead to better IOP controlThe use of multiple second-generation stent systems led to a 20% or higher reduction in IOP in a group of patients with mild-to-moderate, open-angle glaucoma.
Novel dual agonist leads to notable IOP loweringThe drug ONO-9054 led to a greater reduction in IOP and a longer duration of reduction in a small clinical trial compared with latanoprost.
Why 'the more the merrier' doesn't apply to glaucoma monitoringThough ocular hypertension may be the only modifiable risk factor for glaucoma, the second-leading cause of sight loss in the United Kingdom, monitoring for ocular hypertension more than twice a year is not efficient, researchers said.
ROCK inhibitors show promise in glaucoma treatmentA novel class of drugs ‒ rho-kinase, or ROCK inhibitors ‒ appears to lower IOP by relaxing the trabecular meshwork.
Evidence supports cataract surgery for IOP control in exfoliation syndromeCataract surgery lowers IOP in eyes with exfoliation syndrome (XFS) or exfoliation glaucoma (XFG), and it might even change the natural history of glaucoma in eyes with XFS. However, it may also be appropriate to combine phacoemulsification with glaucoma surgery in certain patients with XFG.
Laser-assisted procedure brings ease, precision & safety to deep sclerectomyCO2 laser-assisted sclerectomy surgery performed with a proprietary platform offers an effective and safer alternative to the manual non-penetrating deep sclerectomy procedure for the management of medically uncontrolled open-angle glaucoma.
Novel device safely reduces IOP and glaucoma medication useOne-year after implantation of the Cypass Micro-Stent, study results demonstrate a reduction in IOP and glaucoma medications, as well as a complete lack of sight-threatening adverse events. The implant is placed into the supraciliary space to facilitate suprachoroidal aqueous outflow in glaucoma patients.
Palliative care, support vital for patients who suffer vision lossEven the best ophthalmologists must prepare to support patients who lose vision while in their care, said Robert L. Stamper, MD.